A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Latest Information Update: 11 Jan 2024
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin (Primary) ; Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Tremelimumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms BALTIC
- Sponsors AstraZeneca; AstraZeneca AB
- 11 Jan 2024 This trial has been completed in Hungary as per European Clinical Trials Database record.
- 04 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 13 Apr 2022 Results assessing efficacy, safety, and exploratory ctDNA and PD-L1 analyses from pts who received D + T in Arm A, presented at the 113th Annual Meeting of the American Association for Cancer Research